Neoleukin Therapeutics Stock EBITDA
| NLTXDelisted Stock | USD 0.69 0.01 1.43% |
Neoleukin Therapeutics fundamentals help investors to digest information that contributes to Neoleukin Therapeutics' financial success or failures. It also enables traders to predict the movement of Neoleukin Stock. The fundamental analysis module provides a way to measure Neoleukin Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Neoleukin Therapeutics stock.
Neoleukin |
Neoleukin Therapeutics Company EBITDA Analysis
Neoleukin Therapeutics' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Neoleukin Therapeutics EBITDA | (56.48 M) |
Most of Neoleukin Therapeutics' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Neoleukin Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
CompetitionAccording to the company disclosure, Neoleukin Therapeutics reported earnings before interest,tax, depreciation and amortization of (56.48 Million). This is 106.44% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The ebitda for all United States stocks is 101.45% higher than that of the company.
Neoleukin EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Neoleukin Therapeutics' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Neoleukin Therapeutics could also be used in its relative valuation, which is a method of valuing Neoleukin Therapeutics by comparing valuation metrics of similar companies.Neoleukin Therapeutics is currently under evaluation in ebitda category among its peers.
Neoleukin Fundamentals
| Return On Equity | -0.38 | |||
| Return On Asset | -0.19 | |||
| Current Valuation | (35.02 M) | |||
| Shares Outstanding | 2.35 M | |||
| Shares Owned By Insiders | 16.46 % | |||
| Shares Owned By Institutions | 45.58 % | |||
| Number Of Shares Shorted | 26.4 K | |||
| Price To Earning | (4.60) X | |||
| Price To Book | 0.44 X | |||
| EBITDA | (56.48 M) | |||
| Net Income | (57.56 M) | |||
| Cash And Equivalents | 116.46 M | |||
| Cash Per Share | 2.73 X | |||
| Total Debt | 12.07 M | |||
| Debt To Equity | 0.11 % | |||
| Current Ratio | 12.78 X | |||
| Book Value Per Share | 34.18 X | |||
| Cash Flow From Operations | (45.61 M) | |||
| Short Ratio | 1.70 X | |||
| Earnings Per Share | (12.28) X | |||
| Price To Earnings To Growth | (0.03) X | |||
| Target Price | 1.5 | |||
| Beta | 1.1 | |||
| Market Capitalization | 8.2 M | |||
| Total Asset | 115.95 M | |||
| Retained Earnings | (451.06 M) | |||
| Working Capital | 88.07 M | |||
| Current Asset | 289 K | |||
| Current Liabilities | 1.02 M | |||
| Z Score | -5.73 | |||
| Net Asset | 115.95 M |
About Neoleukin Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Neoleukin Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Neoleukin Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Neoleukin Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Other Consideration for investing in Neoleukin Stock
If you are still planning to invest in Neoleukin Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Neoleukin Therapeutics' history and understand the potential risks before investing.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |